• CD28 targeting
  • How it works
ASH-2024 generation of FcRH5xCD28 bispecific antibodies

ASH-2024 generation of FcRH5xCD28 bispecific antibodies

ASH Annual Meeting 2024 - Sara Majocchi -


Join us at the 66th ASH Annual Meeting in San Diego, California, where Sara Majocchi will present our latest research on innovative approaches for treating multiple myeloma. 🎗️

🌟 Poster #2796: "Generation of FcRH5xCD28 Bispecific Antibodies Synergizing with T-Cell Engagers for Enhanced Multiple Myeloma Treatment" will be exposed and presented on Sunday December 8, 2024, 6 PM - 8 PM

Read poster [PDF] :

aa


San Diego, California, United States

New publication in Cancer Immunology Research

NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control

Read more

LinkedIn